WASHINGTON, D.C. — The National Organization for Rare Disorders (NORD
®) announced a major collaboration today with biotechnology leader Amgen to establish a groundbreaking Learning Collaborative through NORD’s Rare Disease Centers of Excellence Network. Supported by a targeted sponsorship investment from Amgen, this 14-month pilot initiative is designed to tackle one of the most persistent and frustrating gaps in modern medicine: the excessive time it takes to secure an accurate diagnosis for rare diseases.
By bringing together five to eight participating institutions from the prestigious NORD network, the initiative aims to address deep-seated challenges in diagnosing and caring for individuals living with rare autoimmune diseases. Initially, the collaborative will concentrate its efforts on two complex and often misunderstood conditions: IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED). Both conditions are notoriously difficult to recognize in clinical practice and typically require coordinated, multi-specialty medical care that spans several departments, creating significant hurdles for patients and healthcare providers alike.
Through this newly forged pilot program, clinicians operating within participating NORD Rare Disease Centers of Excellence will partner directly with patients, family caregivers, and disease-specific advocacy organizations. Together, these stakeholders will thoroughly examine where the healthcare journey breaks down, focusing specifically on initial symptom recognition, the referral process, treatment decision-making, and long-term care coordination. By drawing directly upon real-world clinical experience, invaluable patient insights, and structured reviews of existing care pathways, the collaborative will pinpoint concrete opportunities for system-wide improvement and develop practical, actionable resources for frontline clinicians.
The architecture of the initiative is intentionally dual-focused, designed to generate two distinct types of learning outcomes. First, it will yield disease-specific approaches aimed at dramatically improving clinical recognition and streamlining care pathways specifically for IgG4-RD and TED. Second, it will capture broader, macro-level insights concerning diagnostic delays, specialist referral bottlenecks, and multi-disciplinary care coordination. These broader lessons hold immense potential, as they may ultimately be adapted and applied to a wide array of other rare diseases facing similar systemic hurdles. Participating medical centers will regularly share their findings, allowing the network to refine and scale approaches that can be successfully adopted across diverse healthcare institutions.
“When NORD established its Rare Disease Centers of Excellence network, our vision was to bring together the expertise and resources of leading medical institutions to tackle challenges that no single institution could solve alone,” said Pam Gavin, President and Chief Executive Officer of NORD. “Amgen is committed to rare diseases and recognized the potential of this network and stepped forward to help put that vision into action. By working across institutions and alongside patients and clinicians, we have an opportunity to address challenges specific to these two diseases while developing approaches that could benefit many more rare disease communities.”
This newly announced Learning Collaborative also directly advances the overarching goals of SPAARK—an acronym for Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge. SPAARK is an Amgen-led alliance comprising 10 prominent advocacy and professional organizations, including NORD, that share a unified mission: reducing the time required to diagnose a rare autoimmune disease by 50 percent by the year 2036.

For patients and their families, the initiative addresses a harrowing reality of chronic illness management. Navigating a medical landscape filled with misdiagnoses, contradictory opinions, and fragmented care can take an immense emotional and physical toll.
“As a caregiver to my husband, Andy, who lives with IgG4-related disease, I know firsthand how overwhelming it can be to navigate a complex disease and find the right answers and care,” said Kat Provencher, Director of Patient Advocacy at the IgG4ward! Foundation. “For families like ours and countless others, the challenges don’t end with a diagnosis. Coordinating care across specialists and understanding the path forward can be just as difficult. What gives me hope about this collaboration is that patients and caregivers will have a voice in identifying where the system falls short and helping shape solutions that could make the journey easier for others.”
The medical community has long acknowledged that the road to appropriate care for rare autoimmune conditions is fraught with obstacles. Medical professionals often encounter these rare presentations infrequently, leading to missed signs and delayed referrals to appropriate specialists.
“For too many people living with rare autoimmune diseases, the path to diagnosis and appropriate care is long and often filled with uncertainty,” said Paul Burton, M.D., Ph.D., senior vice president and chief medical officer at Amgen. “We believe patients deserve answers sooner. Through our collaboration with NORD and the members of SPAARK, we are bringing together diverse perspectives and expertise to address barriers to timely diagnosis, accelerate progress and help more people get the care and support they need.”
Established originally in 2021, NORD’s Rare Disease Centers of Excellence network has grown into a formidable medical alliance, currently encompassing 49 designated centers that span more than 170 affiliated medical and research institutions nationwide. The network was expressly built to connect specialized clinical expertise with institutional resources to bridge historical gaps in rare disease diagnosis and clinical care. The introduction of the Learning Collaborative builds squarely upon that solid foundation, creating a formal, structured environment for institutions to learn from one another’s successes and setbacks while developing pragmatic approaches to shared clinical challenges.
To maintain the highest standards of integrity and trust, NORD will maintain independent scientific oversight over all aspects of the collaborative. The resulting educational resources will be carefully developed to support evidence-based, patient-centered care without endorsing or promoting any specific pharmaceutical product, medication, or proprietary treatment approach.
Founded in 1983, the National Organization for Rare Disorders (NORD) operates as a leading independent, nonpartisan nonprofit organization dedicated to improving the health, well-being, and overall quality of life for the more than 30 million Americans currently living with rare diseases. Representing more than 350 disease-specific member patient organizations alongside its extensive network of Rare Disease Centers of Excellence, NORD continues to advance comprehensive care, scientific research, targeted education, and robust public policy advocacy.
